Recommended

New webinar: Simplify your move from a vial to a prefilled syringe
New webinar with Fujifilm: Monocyte activation test (MAT): Insight into examining regulations and markets prospects
Join our webinar: An alternative medium to support sterility testing using the Growth Direct® Rapid Sterility System
Join now: Pharmaceutical continuous manufacturing: what’s next for industry?
Discover more in our new application note: validating recombinant cascade reagents in 3 simple steps
Join our webinar: Unmasking the unknown: how mass spectrometry delivers accurate identifications

References –  Recommendations and considerations for bacteriophage therapy usage in clinical settings by Snehit Satish Mhatre – EPR Issue 3, 2023

  1. O’neill J. (2014). Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Antimicrob. Resist. Available online at: http://amr-review.org/
  2. Bassetti M, Poulakou G, Ruppe E, et al. (2017). Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach. Intensive Care Med. 43, 1464–1475. 10.1007/s00134-017-4878-x
  3. Woitschach F, Kloss M, Schlodder K, et al. (2022). Bacterial adhesion and biofilm formation of Enterococcus faecalis on Zwitterionic Methylmethacrylat and Polysulfones. Cell. Infect. Microbiol., Volume 12 – 2022 | https://doi.org/10.3389/fcimb.2022.868338
  4. Kutter E, De Vos D, Gvasalia G, et al. (2010). Phage therapy in clinical practice: treatment of human infections. Pharm. Biotechnol. 11, 69–86. 10.2174/138920110790725401
  5. Villarroel J, Larsen MV, Kilstrup M, Nielsen M. (2017). Metagenomic analysis of therapeutic PYO phage cocktails from 1997 to 2014. Viruses 9:E328. 10.3390/v9110328
  6. Abedon ST. (2017). Information phage therapy research should report. Pharmaceuticals 10:E43.
  7. Furfaro L, Payne M, Chang B. (2018). Bacteriophage Therapy: Clinical trials and regulatory hurdles. Front Cell Infect Microbiol. 10.3389/fcimb.2018.00376
  8. Górski A, Bollyky PL, Przybylski M, et al. 2018. Perspectives of phage therapy in non-bacterial infections. Front Microbiol 9:3306.https://doi.org/10.3389/fmicb.2018.03306.
  9. van de Sande WWJ, Vonk AG. 2019. Mycovirus therapy for invasive pulmonary aspergillosis? Med Mycol 57:S179–S188. https://doi.org/10.1093/mmy/myy073.3.
  10. Aslam S, Lampley E, Wooten D, et al. 2020. Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States. Open Forum Infect Dis 7: ofaa389. https://doi.org/10.1093/ofid/ofaa389.
  11. Bao J, Wu N, Zeng Y, et al. 2020. Non-active antibiotic and bacteriophage synergism to successfully treat recurrent urinary tract infection caused by extensively drug-resistant Klebsiella pneumoniae. Emerg Microbes Infect 9:771–774. https://doi.org/10.1080/22221751.2020.1747950.
  12. Plaut S. 2019. Regulatory considerations for bacteriophage products, p 342. In Gorski AMR, Borysowski J (ed), Phage therapy: a practical approach. Springer, Berlin, Germany.
  13. Liu D, Van Belleghem JD, de Vries CR, et al. 2021. The safety and toxicity of phage therapy: a review of animal and clinical studies. Viruses 13:1268. https://doi.org/10.3390/v13071268.
  14. Popescu M, Van Belleghem JD, Khosravi A, Bollyky PL. 2021. Bacteriophages and the immune system. Annu Rev Virol https://doi.org/10.1146/ annurev-virology-091919-074551.
  15. Van Belleghem J, Dąbrowska K, Vaneechoutte M, et al. 2018. Interactions between bacteriophage, bacteria, and the mammalian immune system. Viruses 11:10. https://doi.org/10.3390/v11010010.
  16. Roach DR, Leung CY, Henry M, et al. 2017. Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen. Cell Host Microbe 22:38–47. https://doi.org/10 .1016/j.chom.2017.06.018.
  17. Khatami A, Lin RCY, Petrovic-Fabijan A, et al. 2021. Bacterial lysis, autophagy and innate immune responses during adjunctive phage therapy in a child. EMBO Mol Med 13:e13936. https://doi.org/10.15252/emmm.202113936
  18. Philipson C, Voegtly L, Lueder M, et al. (2018). Characterizing Phage genomes for therapeutic applications. Viruses 2018, 10, 188; doi:10.3390/v10040188
  19. Anderson B, Rashid MH, Carter C, et al. 2011. Enumeration of bacteriophage particles: comparative analysis of the traditional plaque assay and realtime qPCR- and nanosight-based assays. Bacteriophage 1:86–93. https:// doi.org/10.4161/bact.1.2.15456.
  20. Schooley RT, Biswas B, Gill JJ, et al. 2017. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother 61:e00954-17. https://doi.org/10.1128/AAC.00954-17.
  21. . Luong T, Salabarria AC, Roach DR. 2020. Phage therapy in the resistance era: where do we stand and where are we going? Clin Ther 42:1659–1680. https://doi.org/10.1016/j.clinthera.2020.07.014.
  22. Dąbrowska K, Abedon ST. 2019. Pharmacologically aware phage therapy: pharmacodynamic and pharmacokinetic obstacles to phage antibacterial action in animal and human bodies. Microbiol Mol Biol Rev 83: e00012-19. https://doi.org/10.1128/MMBR.00012-19.
  23. Dabrowska K. 2019. Phage therapy: what factors shape phage pharmacokinetics and bioavailability? Systematic and critical review. Med Res Rev 39:2000–2025. https://doi.org/10.1002/med.21572.
  24. Kuipers S, Ruth MM, Mientjes M, et al. 2019. A Dutch case report of successful treatment of chronic relapsing urinary tract infection with bacteriophages in a renal transplant patient. Antimicrob Agents Chemother 64:e01281-19. https://doi.org/10.1128/AAC .01281-19.